Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) CEO Brian Lian sold 216,130 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $70.83, for a total value of $15,308,487.90. Following the completion of the transaction, the chief executive officer now owns 2,304,927 shares in the company, valued at approximately $163,257,979.41. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Brian Lian also recently made the following trade(s):
- On Wednesday, August 21st, Brian Lian sold 1,000 shares of Viking Therapeutics stock. The shares were sold at an average price of $69.90, for a total transaction of $69,900.00.
- On Monday, August 19th, Brian Lian sold 112,870 shares of Viking Therapeutics stock. The shares were sold at an average price of $65.80, for a total transaction of $7,426,846.00.
- On Tuesday, July 30th, Brian Lian sold 115,859 shares of Viking Therapeutics stock. The stock was sold at an average price of $57.58, for a total transaction of $6,671,161.22.
Viking Therapeutics Stock Performance
NASDAQ VKTX opened at $70.47 on Friday. Viking Therapeutics, Inc. has a twelve month low of $8.28 and a twelve month high of $99.41. The stock has a market cap of $7.81 billion, a PE ratio of -75.77 and a beta of 1.00. The firm has a 50-day simple moving average of $59.08 and a 200 day simple moving average of $63.21.
Institutional Investors Weigh In On Viking Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the business. Sanctuary Advisors LLC acquired a new stake in Viking Therapeutics during the second quarter valued at approximately $190,000. Dana Investment Advisors Inc. boosted its stake in Viking Therapeutics by 242.7% in the 2nd quarter. Dana Investment Advisors Inc. now owns 9,943 shares of the biotechnology company’s stock valued at $527,000 after buying an additional 7,042 shares in the last quarter. Aristides Capital LLC grew its position in Viking Therapeutics by 120.0% in the second quarter. Aristides Capital LLC now owns 11,000 shares of the biotechnology company’s stock valued at $583,000 after acquiring an additional 6,000 shares during the period. Cetera Investment Advisers raised its stake in Viking Therapeutics by 114.0% during the second quarter. Cetera Investment Advisers now owns 49,311 shares of the biotechnology company’s stock worth $2,614,000 after acquiring an additional 26,270 shares in the last quarter. Finally, Truist Financial Corp lifted its holdings in shares of Viking Therapeutics by 357.1% during the second quarter. Truist Financial Corp now owns 26,049 shares of the biotechnology company’s stock valued at $1,381,000 after acquiring an additional 20,350 shares during the period. Institutional investors own 76.03% of the company’s stock.
Analyst Ratings Changes
Several brokerages have weighed in on VKTX. Maxim Group reaffirmed a “buy” rating and issued a $120.00 target price on shares of Viking Therapeutics in a research report on Tuesday, June 4th. StockNews.com upgraded Viking Therapeutics to a “sell” rating in a report on Wednesday, July 31st. JPMorgan Chase & Co. initiated coverage on shares of Viking Therapeutics in a research note on Wednesday, September 11th. They issued an “overweight” rating and a $80.00 target price for the company. Morgan Stanley reissued an “overweight” rating and set a $105.00 price objective on shares of Viking Therapeutics in a report on Thursday, September 12th. Finally, Raymond James boosted their target price on shares of Viking Therapeutics from $116.00 to $118.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 25th. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Viking Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $108.60.
View Our Latest Stock Analysis on VKTX
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Read More
- Five stocks we like better than Viking Therapeutics
- How to Use the MarketBeat Stock Screener
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- MarketBeat Week in Review – 9/16 – 9/20
- Manufacturing Stocks Investing
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.